1. News
  2. Business Wire
  3. Business

Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations

Business Wire | January 30, 2014 02:57 IST

Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations

Ex - US & Ex - UK Medical Media Only

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

Empagliflozin Data
A total of eight clinical and pre-clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with Type 2 Diabetes (T2D).

Details of clinical empagliflozin presentations and published abstracts are as follows:1

Tuesday, 24 September, 12:30–13:30 CET, General Poster Session

  • Empagliflozin as Add-on to Basal Insulin for 78 Weeks Improves Glycemic Control and Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM) (Presenting Author: J. Rosenstock) [Poster No. 931]
  • Safety and Efficacy of Empagliflozin Monotherapy in a 52-Week Study in Japanese Patients with Type 2 Diabetes Mellitus (Presenting Author: H. J. Woerle) [Poster No. 930]
  • Metabolic Response to Sodium Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin in Patients with Type 2 Diabetes (T2D) (Presenting Author: E. Ferrannini) [Poster No. 932]

Tuesday, 24 September, 13:45–14:45 CET, General Poster Session

  • Empagliflozin Improves Blood Pressure in Patients with Type 2 Diabetes (T2DM) and Hypertension (Presenting Author: I. Tikkanen) [Poster No. 942]
  • Empagliflozin Improved Glycemic Parameters and Cardiovascular Risk Factors in Patients with Type 2 Diabetes (T2DM): Pooled Data from Four Pivotal Phase III Trials (Presenting Author: T. Hach) [Poster No. 943]
  • Design of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus (Presenting Author: S. E. Inzucchi) [Poster No. 944]

Wednesday, 25 September, 12:30–13:30 CET, General Poster Session

  • Empagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Stage 3A, 3B and 4 Chronic Kidney Disease (CKD) (Presenting Author: A. Mithal) [Poster No. 952]

Thursday, 26 September, 15:00 – 16:30 CET, Oral Presentation

  • The Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor Empagliflozin Improves Glycemic Control in Patients with Type 1 Diabetes: a Single-Arm Clinical Trial (Presenting Author: B. A. Perkins) [Oral Presentation No. 183]

* Empagliflozin is an investigational compound. Its safety and efficacy have not been established.

Linagliptin Data
A total of nine clinical and pre-clinical abstracts for linagliptin will also be presented. Linagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood glucose.2

Details of all clinical presentations and published abstracts are as follows:1

Wednesday, 25 September, 10:45 – 12:15 CET, Oral Presentation

  • Baseline Characteristics of Participants Enrolled in the Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Early Type 2 Diabetes (CAROLINA) (Presenting Author: J. Rosenstock) [Oral Presentation No. 73]

Wednesday, 25 September, 12:30 – 13:30 CET, General Poster Session

  • Efficacy and Safety of Linagliptin as Add-On Therapy to Basal Insulin and Metformin in Patients with Type 2 Diabetes (Presenting Author: S. Durán-Garcia) [Poster No. 892]

Wednesday, 25 September, 15:00 – 16:30 CET, Oral Presentation

  • Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (Presenting Author: O. E. Johansen) [Oral Presentation No. 112]
  • Linagliptin and the Angiotensin II Receptor Blocker Telmisartan Show Comparable Efficacy but Different Renoprotective Pathways in Rats with 5/6 Nephrectomy (Presenting Author: B. Hocher) [Oral Presentation No. 143]

Thursday, 26 September, 10:45 – 12:15 CET, Oral Presentation

  • Insights into the Mechanism of Action of Linagliptin in Reducing Ischaemic Brain Damage Following Stroke in Diabetic and Non-Diabetic Mice (Presenting Author: V. Darsalia) [Oral Presentation No. 152]

Thursday, 26 September, 12:30 – 13:30 CET, General Poster Session

  • Renal Safety and Outcomes with Linagliptin: Meta-Analysis of Individual Data for 5466 Patients with Type 2 Diabetes (Presenting Author: M. von Eynatten) [Poster No. 913]
  • Linagliptin versus Placebo followed by Glimepiride in Type 2 Diabetes Patients with Moderate to Severe Renal Impairment (Presenting Author: P-H. Groop) [Poster No. 914]

Thursday, 26 September, 13:45 – 14:45 CET, General Poster Session

  • Safety and Tolerability of Linagliptin in 7400 Patients with Type 2 Diabetes: A Pooled Comprehensive Analysis of Prospective Safety Reporting in Placebo-Controlled Studies (Presenting Author: M. Lehrke) [Poster No. 986]
  • Renal Safety of Linagliptin in Elderly Patients with Type 2 Diabetes: Analysis of Pooled Patient Data From 7 Phase 3 Clinical Trials (Presenting Author: A. H. Barnett) [Poster No. 926]

Linagliptin, which is marketed as Trajenta® 5mg tablets in Europe, is a once-daily tablet used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Linagliptin is the only approved DPP-4 inhibitor that does not require dose adjustments regardless of renal or hepatic function.

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

var zflag_nid="1263"; var zflag_cid="22"; var zflag_sid="1"; var zflag_width="468"; var zflag_height="20"; var zflag_sz="22"; var zflag_click="[INSERT_CLICK_TRACKER_MACRO]";






 

 
 
 
Recent Reports
News